Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals, and produces prolonged clinical remission in patients with severe ...

No fatal adverse events occurred, and benralizumab was well tolerated. “The ABRA [Acute exacerbations treated with BenRAlizumab] study is the first trial to target the eosinophilic treatable trait, ...

Benralizumab, marketed by Astrazeneca (AZN), targets a specific type of white blood cells, called eosinophils, which is responsible for inflammation and damage in the lungs.

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

The drug, which is called benralizumab, is the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. A trial has shown that using the drug can cut ...

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

Benralizumab generic Benralizumab is a type of monoclonal antibody which is prescribed as an add-on maintenance treatment for treating severe eosinophilic asthma in patients 12 years of age and ...

Benralizumab is a much-needed treatment option, with data showing that not only is remission an achievable goal for EGPA patients, but benralizumab can also help patients taper off steroid therapy.” ...

Send comments and news tips to news@medscape.net. Cite this: Benralizumab Decreases Eosinophils, but Not Symptoms, in Eosinophilic Esophagitis - Medscape - July 29, 2024.